Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Government Report On Drug Regulation Seeks To Increase Transparency

This article was originally published in PharmAsia News

Executive Summary

BEIJING - As part of a drive to open China's drug regulatory system to public scrutiny and foster international cooperation, the Chinese government has released a ground-breaking report on the current state of its industry oversight

You may also be interested in...



Beijing’s New Fast-track Review For Innovative Medicines Might Be Open Only To Made-in-China Drugs

BEIJING - China's fast-track review process for certain classes of new drugs, unveiled earlier this month, marks an advance in the country's budding support for innovative medicines, but also might be open only to domestically made products, according to Chinese and American lawyers

Beijing’s New Fast-track Review For Innovative Medicines Might Be Open Only To Made-in-China Drugs

BEIJING - China's fast-track review process for certain classes of new drugs, unveiled earlier this month, marks an advance in the country's budding support for innovative medicines, but also might be open only to domestically made products, according to Chinese and American lawyers

China Recalls Contaminated TCM Injection

SHANGHAI - China has ordered a recall of two batches of acanthopanax-based injections, also know as Siberian ginseng, after reports of serious adverse reactions that caused the death of three patients in Yunan Province, China's Ministry of Health announced Oct. 11

Related Content

Latest News
UsernamePublicRestriction

Register

SC069054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel